The estimated Net Worth of Wende S Hutton is at least $12.6 Million dollars as of 8 October 2014. Wende Hutton owns over 49,276 units of Chimerix Inc stock worth over $2,150,128 and over the last 11 years Wende sold CMRX stock worth over $10,465,698.
Wende has made over 2 trades of the Chimerix Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Wende bought 49,276 units of CMRX stock worth $788,416 on 8 October 2014.
The largest trade Wende's ever made was selling 674,771 units of Chimerix Inc stock on 23 October 2013 worth over $10,465,698. On average, Wende trades about 144,809 units every 70 days since 2013. As of 8 October 2014 Wende still owns at least 2,500,149 units of Chimerix Inc stock.
You can see the complete history of Wende Hutton stock trades at the bottom of the page.
Wende's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 340, DURHAM,, NC, 27713.
Over the last 11 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex, and Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Chimerix Inc executives and other stock owners filed with the SEC include: